Atlas Trials

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Clinical trial NCT05680818 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05680818
Sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Autosomal Dominant Hypocalcemia (ADH)
Start date
2023-01-06
Primary completion
2025-08-22
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.